Nov 29, 2021 10:25am EST BioReference Laboratories Announces Readiness for COVID-19 Testing if the Omicron COVID-19 Variant Emerges in The U.S.
Nov 29, 2021 8:00am EST OPKO Health Announces Participation in Piper Sandler 33rd Annual Virtual Healthcare Conference
Oct 28, 2021 4:15pm EDT OPKO Health Reports 2021 Third Quarter Business Highlights and Financial Results
Oct 25, 2021 10:57am EDT OPKO Health to Report Third Quarter 2021 Financial Results on October 28, 2021
Sep 24, 2021 4:24pm EDT Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency
Sep 14, 2021 8:00am EDT LeaderMed Group and OPKO Health Form Joint Venture to Develop and Commercialize Oxyntomodulin and Factor VIIa-CTP in China and Other Asian Territories
Aug 30, 2021 4:17pm EDT OPKO Health Completes Enrollment in Phase 2 Trial Evaluating RAYALDEE as a Treatment for Symptomatic COVID-19 Outpatients
Aug 26, 2021 9:30am EDT Rite Aid, in Partnership with the U.S. Department of Health and Human Services, BioReference Laboratories and New York State, Announces ‘Back to School’ COVID-19 Testing Program
Aug 16, 2021 9:55am EDT BioReference Laboratories Acquires U.S. Ariosa Centralized Laboratory Prenatal Testing Business